Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Uterine Cervical Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1 Malignant mesenchymal tumor 1 Colorectal Neoplasms 1 Carcinoma 1 Anus Neoplasms 1

Interventions

Specimen Handling 9 Magnetic Resonance Spectroscopy 9 Cisplatin 6 Biopsy 5 Paclitaxel 4 pembrolizumab 3 Platinum 3 Immunoglobulin G 3 Disulfides 3 Cetuximab 3 Carboplatin 3 1,2-diaminocyclohexaneplatinum II citrate 3 (225)Ac-DOTA-c(RGDyK) 3 ipatasertib 2 cemiplimab 2 Taxes 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiosurgery 2 Radiation 2 Docetaxel 2 Cytoreduction Surgical Procedures 2 Bevacizumab 2 ALT-803 2 peposertib 1 peginterferon alfa-2b 1 interferon gamma-1b 1 fludarabine phosphate 1 fludarabine 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Carcinoma × NHS-IL12 immunocytokine × Clear all

NCT01417546 2021-10-18

NHS-IL12 for Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

Malignant mesenchymal tumor, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡